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Abstract: The coupling of proline- and azetidinone-substituted alkenes to 2-azidobenzoic 
and 2-azidobenzenesulfonic acid gives precursors that undergo intramolecular azide to 
alkene 1,3-dipolar cycloadditions to give imine-, triazoline- or aziridine-containing 
pyrrolo[1,4]benzodiazepines (PBDs), pyrrolo[1,2,5]benzothiadiazepines (PBTDs), and 
azetidino[1,4]benzodiazepines. The imines and aziridines are formed after loss of nitrogen 
from a triazoline cycloadduct. The PBDs are a potent class of antitumour antibiotics. 
Keywords: cycloaddition; 1,3-dipole; azide; pyrrolobenzodiazepine; azetidinone; 
antitumour; antibiotic; β-lactam 
 
1. Introduction 
The pyrrolobenzodiazepines (PBDs), of which the natural products abbeymycin (1), DC-81 (2) and 
fuligocandin B (3) (Figure 1) are typical examples, are a class of molecule that has attracted significant 
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interest due the antitumour and antibiotic activity of several members [1–5]. Synthetic hybrids [5–8] and 
dimers [5,9–11] have also shown significant biological activity and members of the dimer class have 
entered Phase II clinical development as antitumour compounds. PBDs with additional fused rings such 
as the circumdatin (4) [12], bretazenil (5) [13] and the 1,2,3-triazolo-fused system 6 [14] are attractive 
as potential antitumour compounds, neurological agents, and protease inhibitors, respectively. As a result 
of this interest, the replacement of the PBD pyrrole ring with other rings has attracted attention [5,15] 
and hence pyrido- [16], oxazolo- [17], thiazolo- [18] and imidazo- [19–21] analogues are all known. The 
replacement of the PBD tertiary amide with a sulfonamide leads to the pyrrolobenzothiadiazepines 
(PBTDs) which are synthetic analogues of the PBDs [22]. The PBTDs have received much less attention 
than the PBDs, but it is known that PBTDs 7–9 are useful as non-nucleosidic reverse transcriptase 
inhibitors [23], potent leukemia cell-line inhibitors [24] and Glut-1 transporter inhibitors with 
chemotherapeutic potential [25], respectively. 
Figure 1. Pyrrolobenzodiazepine (PBD) and pyrrolobenzothiadiazepine (PBTD) structures of interest.  
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We reported previously [26] that the 1,2,3-triazolo-fused PBDs and PBTDs 11 (Figure 2) are 
available via intramolecular azide to alkyne 1,3-dipolar cycloaddition of 1-(azidoaryl)-2-alkynyl 
pyrroles 10, and have recently shown [25] that the 1-(azidoaryl)-2-cyano pyrroles 12 give the  
1,2,3,4-tetrazolo-fused PBD and PBTD systems 13.  
Figure 2. Previous examples of PBDs and PBTDs synthesized by 1,3-dipolar cycloaddition. 
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In preliminary work involving alkenes, we demonstrated that 1-(azidoaryl)-2-alkenyl pyrroles 14 and 
15 gave the aziridino-fused PBD 16 and PBTD 17 [27]. In this paper, we report the full details for the 
synthesis of compounds 16 and 17 and also discuss several new intramolecular cycloadditions involving 
the previously unreported 1-(azidoaryl)-2-alkenyl pyrroles 18 (Figure 3) along with the reactions of a 
second new series of compounds, the 1-(azidoaryl)-4-alkenyl-azetidin-2-ones 19. 
Figure 3. Additional alkene based substrates studied in this paper. 
 
2. Results and Discussion 
2.1. Synthesis and Reactivity of the Pyrrolo-Based Systems  
The largest and most researched class of PBDs, those represented by abbeymycin (1) and DC-81 (2), are 
able to interact with nucleophilic guanidine residues in the minor groove of DNA, a process that is reliant 
upon the presence of an electrophilic imine or carbinolamine based functional group [5]. It is of note 
that the (S)-chiral center that is present in the 3-dimensional structure of these PBDs gives the molecules 
a shape which enables them to twist into the DNA minor groove meaning that most syntheses are based 
upon derivatives of (S)-proline. It is known that intramolecular 1,3-dipolar cycloadditions of azides to 
alkenes can lead to either imines or aziridines via triazoline intermediates [28,29]. On this basis, we 
anticipated that we could access imine or aziridine containing PBDs using intramolecular 1,3-dipolar 
cycloadditions between azides and alkenes using alkenes derived from (S)-proline. Whilst we were 
interested in the possibility of producing an imine, we were more intrigued by the possibility of 
producing an aziridine due the known propensity [30] of aziridines to function as electrophiles and the 
potential biological activity that a novel system of this type might offer. We settled upon two approaches, 
as shown in Scheme 1. 
In the first system, (S)-prolinol (20) was converted into the unstable alkene 24 using a modified 
literature protocol [31]. Thus, S-prolinol (20) was protected as the carbamate 21, oxidized to the aldehyde 
22 and then converted to the N-protected alkene 23 by Wittig reaction. In-situ deprotection and coupling 
of the deprotected alkene 24 to 2-azidobenzoyl chloride or 2-azidobenzenesulfonyl chloride 27a/b gave 
the cycloaddition precursors 14 and 15 in 32% and 20% yield, respectively, from the carbamate 23. 
Heating compound 14 in chloroform gave a ~1:1 mixture of the imine 25 and the aziridine 16 (55% 
combined yield) whereas heating compound 15 in the same solvent gave the aziridine 17 as the only 
isolable product in 44% yield. 
We assume these reactions proceed via intramolecular 1,3-dipolar cycloaddition to give an 
intermediate triazoline which then undergoes loss of two nitrogen atoms. It is of note that Broggini 
explored a similar process with halogenated aryl systems and obtained the triazolines 26 [32]. The 
presence of the aziridine ring in compounds 16 and 17 was clear in the NMR spectra from the extra CH2 
and CH groups and from the diagnostic lack of CH2 geminal coupling in the aziridine CH2. 
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Scheme 1. Synthesis of aziridinopyrrolobenzodiazepines and aziridinopyrrolobenzothiadiazepines. 
 
Mass spectroscopy confirmed loss of two nitrogen atoms and precluded the triazoline. The relative 
stereochemical assignment in compounds 16 and 17 was made on the basis of the CH/CH coupling 
constant at 8–10 Hz, the lack of a CH to CH nOesy correlation and the presence of aziridine CH2 to 
pyrrolidine CH correlation, and the unequivocal assignment of Broggini's system by X-ray 
crystallography [32]. Stereochemistry at the aziridine nitrogen was not determined. Although we used 
(S)-prolinol as the starting material (due to its ease of availability), we did not seek to confirm absolute 
stereochemical assignments, although it is of note that Sato and co-workers reported that the alkene 24 
retains the (S)-configured centre [31]. 
In our second approach, also shown in Scheme 1, we coupled (S)-prolinol to 2-azidobenzoyl chloride 
or 2-azidobenzenesulfonyl chloride 27a/b (80%–96%) and oxidized the alcohols 28 and 29 under Swern 
conditions to give the aldehydes 30 and 31 (72%–80%). Attempts to react the aldehydes 30 and 31 with 
(methylene)triphenylphosphorane were unsuccessful meaning that a more efficient route (compared to 
the synthesis and in-situ deprotection of 23) to the alkenes 14 and 15 was not possible. However, 
reactions of these aldehydes with (carbethoxymethylene)triphenylphosphorane in toluene were 
successful. In the case of reaction with aldehyde 30, the alkene 32 was isolated in 51% yield and then 
heated in chloroform, whereupon it converted into the aziridine 33 as a 1:1 mixture of diastereoisomers 
in 30% yield. In the case of aldehyde 31, the alkene 34 could not be isolated and the aziridine 35 was 
isolated as the only product in 34% yield from the aldehyde, this time as a single diastereoisomer, 
possibly due to the lower temperature at which reaction occurred. We assigned the aziridine-
CH/pyrrolidine-CH stereochemistry on the same basis as that described above, but were unable to 
determine the stereochemistry at the CHCO2Et chiral center. We assume that these products arise as a 
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result of azide to alkene cycloaddition and formation of an intermediate triazoline 39, which then 
undergoes loss of two nitrogen atoms. As discussed previously, this loss of nitrogen is known  
behavior in alkene to azide cycloaddition processes [28,29]. We also studied reactions involving  
(2-azido-4-benzyloxy-5-methoxy)benzoyl chloride 27c (X = CO, R1 = OMe, R2 = OBn) due to this 
having the substitution pattern present in the natural product DC-81 (2). This azide was available in six 
steps from commercially available 4-hydroxy-3-methoxybenzoic acid using a literature procedure [33,34]. 
Attempts to couple this acid chloride to the alkene 24 were unsuccessful and led to significant 
degradation of the azide staring material–possibly as a result of its intolerance to the extreme in-situ 
conditions under which the alkene 24 was generated [31]. However, coupling of the acid chloride 27c to 
prolinol was successful and subsequent oxidation gave the aldehyde 37. Attempted reaction of this 
aldehyde with (methylene)triphenylphosphorane was again unsuccessful. However, reaction with 
(carbethoxymethylene)triphenylphosphorane gave a new product. As was observed previously with 
aldehyde 31, the alkene 38 was not isolable. This time, however, the product was unexpectedly found to 
be the “reduced” pyrrolobenzodiazepine 40, formed as a single diastereoisomer in 21% yield from the 
aldehyde, with stereochemistry consistent with that discussed above (no CH to CH correlation by nOesy 
and a strong CH2CO2Et to pyrrolidine CH correlation). We assume that this product arises as a result of 
a free-radical based loss of nitrogen from the triazoline 39 followed by hydrogen abstraction from the 
toluene solvent rather than imine/aziridine formation as observed previously. 
2.2. Synthesis and Reactivity of the Azetidino Based Systems 
In order to obtain further examples of these cycloaddition processes, we next turned our attention to 
the use of 4-alkenyl-2-azetidinones (Scheme 2) as coupling partners for 2-azidobenzoyl chloride (27a). 
We chose azetidinone systems due to our long-standing interest in the chemistry and biological 
applications of the β-lactams and their derivatives [35,36], and also due to the lack of literature examples 
of azetidino analogues of the PBDs. The 4-alkenyl-2-azetidinones 41 were synthesized in 58%–60% 
yield using a [2+2]-cycloaddition between a diene and chlorosulfonyl isocyanate followed by work-up 
to remove the N-sulfonyl group. Whilst the 4-methyl substituted β-lactam 41a coupled successfully 
(65% yield) to give the 1-(2'-azidobenzoyl)-2-azetidinone 42a, we were unable to obtain the corresponding 
demethyl system 42b from the β-lactam 41b. We thus converted the azetidinones 41a/b into the 
corresponding azetidinethiones 43a/b by reaction with Lawesson's reagent, reasoning that this may result 
in a nitrogen atom that was more nucleophilic, and in fact, the two azetidin-2-thiones 43a/b reacted 
successfully with 2-azidobenzoyl chloride (27a) to give the 1-(2'-azidobenzoyl)-2-azetidinthiones 44a/b 
in 84% and 71% yield, respectively. Each of the three azido alkenes 42a and 44a/b behaved differently 
when heated to reflux in boiling solvents. Compound 42a gave the imine 45 (38%) when heated in 
boiling chloroform for 72 h; compound 44a when heated in boiling chloroform also gave the 
corresponding imine 47, but this time formed the isolable triazoline 46 (61% yield) after 72 h and gave 
the imine in 32% yield after a further 7 days in boiling chloroform; compound 44b was stable in 
chloroform at reflux, but gave the aziridine 48 (48% yield) upon 24 h of heating in toluene at reflux. The 
aziridine ring in compound 48 was apparent from the CH2CHCHCH2 connectivity in the system, the 
distinctive lack of geminal proton coupling for the aziridine CH2 and the loss of two nitrogen atoms in 
the mass spectrum. The product was formed as a single diastereoisomer according to the 1H/13C-NMR 
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spectra. Stereochemistry at the aziridine nitrogen was not determined. The CH/CH stereochemistry was 
assigned by correlation to the systems described above on the basis of the similar 8.9 Hz coupling constant. 
Scheme 2. Synthesis and reactivity of 1-(2'-azidobenzoyl)-4-alkenyl-1-azetidin-2-ones/2-thiones. 
 
3. Experimental Section 
3.1. General Information 
Reactions were performed in oven-dried glassware under nitrogen dried through 4 Å molecular sieves 
and delivered through a gas manifold. Work-up procedures were carried out in air. Anhydrous grade 
solvents were freshly distilled using a continuous still under nitrogen. Chloroform was dried over 4 Å 
molecular sieves or distilled over phosphorus pentoxide (3% w/v). Dichloromethane, acetonitrile, ethyl 
acetate and toluene were distilled over calcium hydride (5% w/v) over 4–6 h. Diethyl ether and THF 
were pre-dried over sodium wire, and then distilled over sodium wire (1%–2% w/v) with benzophenone 
(0.2%–0.3% w/v) as an indicator. Other anhydrous solvents were purchased from Fisher Chemicals or 
Sigma-Aldrich. All reactions were monitored by TLC, which was carried out on 0.20 mm  
Macherey-Nagel Alugram® Sil G/UV254 silica gel-60 F254 precoated aluminium plates and visualisation 
was achieved using UV light or vanillin stain. Column chromatography was performed on Merck silica 
gel (0.063–0.200 mm, 60 Å). NMR spectra were recorded on a Bruker DPX-400 or on a Bruker Avance 
500 instrument. IR spectra were recorded on a Nicolet 380 FT-IR instrument as a drop for oils and liquids 
or as neat powders for solids. Mass spectra were recorded on a Bruker Daltonics micrOTOF mass 
spectrometer operating at a positive ion mode under an electrospray ionization (ESI +) method. High 
resolution mass spectra were recorded on a Finnegan MAT 900 XTL instrument operated by the EPSRC 
National Mass Spectrometry service at the University of Swansea. 1-(2'-Azidobenzoyl)pyrrolidine-2-
carbaldehyde [33,34], 2-azidobenzenesulfonic acid [37] and 2'-azido-4-(benzyloxy)-5-methoxybenzoic 
acid [33,34] were synthesized as described in the literature. The synthesis of N-2-ethenyl-1-
ethoxycarbonylpyrrolidine (23) and its deprotection have been described previously [31], but full details 
are included below as we found some modification was necessary. Due to ease of availability, we started 
our synthesis with (S)-prolinol, but we did not seek to confirm the absolute stereochemical integrity of 
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subsequent materials. Full experimental procedures for the synthesis of compounds 16, 17 and 25 have 
not appeared previously, although we have reported this chemistry in preliminary form as part of an 
earlier study [27]. Similarly, we have described the synthesis and use of compounds 41 and 43 before as 
precursors in other chemistry [36], but have not before given detailed experimental procedures. 
Compounds 32–35, 38, 40, 42 and 44–48 are previously unreported. 
3.2. Synthesis and Reactivity of the Pyrrolo-Based Systems 
N-(Ethoxycarbonyl)-prolinol (21). To a stirring solution of S-prolinol (20, 1.00 g, 9.89 mmol) in 4 M 
NaOH (7 mL) was added ethyl chloroformate (1.13 mL, 1.29 g, 11.9 mmol) over 10 min at 0 °C. The 
reaction was stirred at 0 °C for 30 min followed by 30 min at ambient temperature. The reaction solution 
was neutralized with 2M HCl, the aqueous phase was separated and extracted with DCM (3 × 10 mL). 
The combined organic layers were dried (MgSO4), filtered and concentrated under reduced pressure to 
give the crude product 21 (1.64 g, 96%) as a yellow oil which was used directly in the next step. NMR: 
δH (400 MHz, CDCl3): 1.27 (3H, t, J = 7.1, COCH2CH3), 1.57 (1H, m, CHH), 1.74–1.91 (2H, m, CHH 
+ CHH), 1.99–2.08 (1H, m, CHH), 3.31–3.78 (1H, m, NCHH), 3.49–3.54 (1H, m, NCHH), 3.59–3.69 
(2H, m, CH2OH), 3.97–4.03 (1H, m, CH2OH), 4.14 (2H, q, J = 7.1, COCH2CH3), 4.61 (1H, dd, J = 7.6, 
2.6, NCHCH2); δC (100 MHz, CDCl3): 14.7 (CH3), 24.1 (CH2), 28.6 (CH2), 47.3 (CH2), 60.6 (CH), 61.6 
(CH2), 67.3 (CH2), 157.6 (q). IR: υmax (thin film cm−1): 770 (s), 906 (m), 1046 (s), 1106 (s), 1333 (s), 
1379 (s), 1414 (s), 1667 (s), 2876 (w), 2975 (w), 3400–3500 (br). LRMS (ESI+): Found 196.1 [M+Na]+, 
C8H15N4NaO3 requires 196.1. 
N-(Ethoxycarbonyl)-prolinal (22). A 2 M solution of (COCl)2 in DCM (4.72 mL, 9.43 mmol) was diluted 
with dry DCM (12 mL) and cooled to −78 °C under N2. DMSO (1.34 mL, 1.47 g, 18.9 mmol) in DCM 
(5 mL) was added followed by the alcohol 21 (1.36 g, 7.86 mmol) in DCM (5 mL), over 15 min. The 
whole was maintained at −78 °C for 30 min before the addition of Et3N (5.48 mL, 3.98 g, 39.3 mmol) 
dropwise over 10 min. The whole was allowed to reach room temperature over an hour before being 
quenched with a mixture of Et2O (12.5 mL) and H2O (12.5 mL). The organic layer was separated and 
the aqueous phase was extracted with DCM (3 × 10 mL). The combined organics were dried (MgSO4), 
filtered, concentrated under reduced pressure and purified by silica chromatography (20 g) (EtOAc/Hex; 
2:3) to yield the aldehyde 22 as a mixture of rotamers in the form of a yellow oil (1.19 g, 89%). NMR: 
δH (400 MHz, CDCl3): 1.17 & 1.24 (3H, 2 × t, J = 7.1 & 7.1, COCH2CH3), 1.76–1.92 (2H, m, CH2), 
1.93–2.09 (2H, m, CH2), 3.40–3.57 (2H, m, NCH2), 4.02–4.14 & 4.17–4.22 (3H, m, CO2CH2CH3 & 
NCHCHO), 9.48 & 9.56 (1H, 2 × d, J = 2.5, 1.7, CHO); δC (100 MHz, CDCl3): 14.5/14.7 (CH3), 
23.8/24.5 (CH2), 26.6/27.8 (CH2), 46.6/47.1 (CH2), 61.5 (2 × CH2), 64.8/65.1 (CH), 154.7/155.6 (q), 
200.2/200.3 (CHO). IR: υmax (thin film cm−1): 729 (s), 771 (s), 914 (m), 1021 (m), 1102 (s), 1172 (m), 
1341 (s), 1380 (s), 1416 (s), 1466 (s), 1687 (s), 1733 (s), 2872 (m), 2980 (m). LRMS (ESI+): Found 
194.1 [M+Na]+, C8H13NNaO3 requires 194.1. 
N-2-Ethenyl-1-ethoxycarbonylpyrrolidine (23). n-BuLi in hexanes (1.6 M, 10.5 mL, 16.8 mmol) was 
added dropwise over 30 min to a stirring suspension of methyltriphenylphosphonium bromide (5.52 g, 
15.4 mmol) in anhydrous THF (30 mL) at −78 °C under an inert atmosphere of nitrogen. The whole was 
allowed to reach −10 °C and kept at that temperature for 30 min before being cooled back to −78 °C. The 
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aldehyde 22 (1.20 g, 7.02 mmol) in anhydrous THF (5 mL) was added dropwise over 10 min. The whole 
was allowed to warm to −10 °C, and maintained at that temperature for 2 h and then the mixture was 
allowed to reach room temperature overnight. The mixture was quenched with saturated aqueous NH4Cl 
(20 mL) and the aqueous layer was separated and extracted with EtOAc (3 × 10 mL). The combined 
organic layers were dried (MgSO4), filtered, concentrated under reduced pressure and purified by silica 
chromatography (50 g) (EtOAc/Hex; 3:2) yielding an air sensitive product as a mixture of rotamers in 
the form of a pale orange oil (536 mg, 45%). NMR: δH (400 MHz, CDCl3): 1.22–1.27 (3H, br, m, CH3), 
1.71 (1H, bs, CH2CHHCH2), 1.81 (2H, br, m, NCHCH2), 1.97 (1H, m, br, CH2CHHCH2), 3.43 (2H, s, 
br, NCH2), 4.13 (2H, br, m, OCH2), 4.33 (1H, br, m, NCH), 5.04–5.12 (2H, br, m, CH=CH2), 5.72 (1H, 
br, m, CH=CH2); δC (100 MHz, CDCl3): 14.2/14.8 (CH3), 22.6/23.4 (CH2), 31.2/31.9 (CH2), 46.3/46.5 
(CH2), 58.9/59.3 (CH), 60.4/60.8 (CH2), 113.8/114.1 (CH2), 138.2/138.5 (CH), 155.1/155.4 (q). 
N-(2'-Azidobenzoyl)-2-ethenylpyrrolidine (14). To a vigorously stirred suspension of finely ground KOH 
(2.31 g, 41.2 mmol) in ethylene glycol (7.2 mL) was added hydrazine hydrate (0.25 mL, 7.92 mmol) and  
2-ethenyl-1-ethoxycarbonylpyrrolidine (23) (0.2706 g, 1.58 mmol) and the whole was heated to reflux 
(195 °C) for 4 h. The reaction was allowed to reach ambient temperature before being diluted with a 
mixture of Et2O (4 mL) and H2O (4 mL). The thick syrup was extracted with Et2O (3 × 5 mL) and dried 
with finely ground NaOH. Et3N (0.33 mL, 2.37 mmol) was added to the ethereal solution containing the 
amine at 0 °C under an inert atmosphere and was stirred for 10 min before the freshly prepared acid 
chloride 27a (0.48 g, 2.30 mmol) in Et2O (5 mL) was added dropwise over 10 min and the whole was 
allowed to reach ambient temperature overnight. The reaction was diluted with water (20 mL), the 
ethereal layer was separated and the aqueous phase was extracted with ether (3 × 10 mL). The combined 
organics were dried (MgSO4), filtered, concentrated under reduced pressure and purified by silica 
chromatography (21 g) (EtOAc/Hex; 2:3) to yield the product as a mixture of rotamers (0.1230 g, 32%) in 
the form of a yellow oil. NMR: δH (400 MHz, CDCl3): 1.73–2.15 (4H, m, 2 × CH2), 3.17–3.23 &  
3.30–3.36 (1H, m, CHHCH2), 3.64–3.71 & 3.74–3.82 (1H, m, CHHCH2), 4.11–4.15 & 4.84–4.87 (1H, 
br, m, CHCH2), 4.70 & 5.35 (1H, 2 × d, J = 16.9, 17.1, CHHCH), 4.89 & 5.20 (1H, 2 × d, J = 10.3 & 
10.4, CHCHH), 4.89 & 5.20 (1H, 2 × d, J = 10.3 & 10.4, CHCHH), 5.56 & 5.90 (1H, 2 × ddd, J = 6.2, 
10.4, 16.9 & 4.8, 10.4, 17.1, CHCH2) 7.10–7.24 (3H, m, ArH), 7.32–7.45 (1H, m, ArH); δC (100 MHz, 
CDCl3): 22.1/23.6 (CH2), 30.9/32.3 (CH2), 45.9/48.2 (CH2), 58.4/61.1 (CH), 114.5/114.9 (CH2), 
118.4/118.5 (CH), 124.6/125.2 (CH), 127.9/128.3 (CH), 129.6/130.1 (q), 130.2/130.3 (CH), 136.1 (q), 
136.9/137.6 (CH), 166.8/167.4 (q). IR: υmax (thin film cm−1): 750 (s), 932 (s), 1083 (m), 1149 (m), 1292 
(s), 1415 (s), 1449 (s), 1479 (s), 1598 (s), 1631 (s), 2128 (s), 2878 (m), 2973 (m), 3078 (w). LRMS 
(ESI+): Found 265.1 [M+Na]+, 507.2 [2M+Na]+. HRMS (ESI+): Found 265.1064 [M+Na]+, 
C13H14N4NaO requires 265.1060. 
Pyrrolobenzodiazepine (25) and aziridinopyrrolobenzodiazepine (16). The alkene 14 (78.0 mg, 0.32 mmol) 
was dissolved in CHCl3 (10 mL) and heated at reflux under an inert atmosphere of nitrogen for 16 h 
whilst being monitored by TLC (EtOAc/Hex; 3:2). The reaction mixture was concentrated under reduced 
pressure and purified by silica chromatography (20 g) (EtOAc/Hex; 3:2–4:1) to yield two inseparable 
close-running spots on TLC which were found to be the aziridine 16 and the methyl imine 25 in a 1:1 
ratio (estimated by 1H-NMR, 43 mg, 55%). NMR: δH (400 MHz, CDCl3): 1.96–2.06 (2H, m, CH2), 2.00 
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(1H, d, J = 3.6, aziridine CH2), 2.09–2.22 (2H, m, 2 × CHH), 2.18–2.26 (3H, m, CH2 + CHH), 2.27 (3H, 
s, CH3), 2.29–2.37 (1H, m, CHH), 2.53 (1H, d, J = 4.3, aziridine CH2), 2.78 (1H, ddd, J = 9.5, 4.3, 3.6, 
aziridine CH), 3.34 (1H, ddd, J = 9.5, 2.9, 1.6, NCH [aziridine]), 3.45–3.52 (1H, m, NCH), 3.56–3.63 
(1H, m, NCHH), 3.62–3.72 (2H, m, 2 × NCH), 3.74–3.84 (1H, m, NCH2), 3.81–3.95 (1H, m, NCH2), 
7.01 (1H, dt, J 7.9, 0.7, ArH), 7.11 (1H, d, J 8.1, ArH), 7.14–7.18 (2H, m, 2 × ArH), 7.40 (1H, dt,  
J = 7.6, 1.6, ArH), 7.44–7.52 (1H, m, ArH), 7.74 (1H, d, J = 7.9, ArH), 7.93 (1H, dd, J = 7.9, 1.6, ArH); 
δC (100 MHz, CDCl3): 22.4 (CH3), 23.1 (CH2), 24.2 (CH2), 27.9 (CH2), 29.4 (CH2), 32.7 (CH2), 32.9 
(CH2), 44.8 (CH), 46.1 (CH2), 55.6 (CH), 58.1 (CH), 122.0 (CH), 122.9 (CH), 125.5 (CH), 126.4 (CH), 
126.8 (q),127.0 (q), 129.7 (CH),129.8 (CH), 131.2 (CH), 131.4 (CH), 145.6 (q), 145.7 (q), 150.3 (q), 
165.5 (q), 169.9 (q). IR: υmax (thin film cm−1): 907 (s), 1244 (m), 1320 (m), 1403 (m), 1454 (s), 1614 (s), 
1681 (m), 1743 (m), 2876 (w), 2924 (m), 2970 (w). LRMS (ESI+): Found 215.1 [M+H]+, 237.1 
[M+Na]+, 451.2 [2M+Na]+, 665.3 [3M+Na]+. HRMS (ESI+): Found 215.1179 [M+H]+, C13H15N2O 
requires 215.1179. 
N-(2'-Azidobenzenesulfonyl)-2-ethenylpyrrolidine (15). To a stirring suspension of KOH (4.280 g,  
76.5 mmol) in ethylene glycol (15 mL), hydrazine hydrate (0.46 mL, 471 mg, 14.7 mmol) was added 
under nitrogen followed by the ester protected alkene 23 (497 mg, 2.94 mmol), and the whole was heated 
at reflux (195 °C) for 4.5 h. The reaction mixture was cooled to ambient temperature and was diluted 
with Et2O (9 mL) and water H2O (9 mL). The organic layer was separated and the aqueous layer was 
extracted with Et2O (3 × 5 mL) and dried over NaOH. Et3N (0.62 mL, 4.41 mmol) was added to the 
ethereal solution containing the amine at 0 °C and the mixture was stirred for 10 min under an inert 
atmosphere of nitrogen before addition of freshly prepared 2-azidobenzenesulfonyl chloride 27b [which 
was prepared by heating at reflux 2-azidobenzenesulfonic acid (900 mg, 4.41 mmol) with 2M oxalyl 
chloride in DCM (4.4 mL, 8.82 mmol) which was concentrated under reduced pressure and suspended 
in Et2O (10 mL)]. The whole was allowed to reach room temperature overnight. The reaction was diluted 
with water (30 mL), the ethereal layer was separated and the aqueous layer was extracted with Et2O  
(3 × 10 mL). The combined organics were dried (MgSO4), filtered, concentrated under reduced pressure 
and purified by silica chromatography (20 g) (EtOAc/Hex; 1:4) to yield the product as a yellow oil  
(163 mg, 20%). NMR: δH (400 MHz, CDCl3): 1.30–1.40 (1H, m, CHH), 1.83–1.92 (2H, m, CH2),  
2.07–2.10 (1H, m, CHH), 2.92–2.99 (1H, m, CHH), 3.54–3.57 (1H, m, CHH), 3.93–3.98 (1H, m, NCH), 
4.37–4.40 (1H, m, CH=CHH), 4.54 (1H, dd, J = 12.6, 17.8, CH=CHH), 5.30–5.37 (1H, m, CH=CH2), 
7.16 (1H, dd, J = 8.0, 8.0, ArH), 7.45 (1H, dd, J = 8.4, 8.4, ArH), 7.83 (1H, d, J = 8.4, ArH), 7.91 (1H, 
d, J = 8.0, ArH). IR: υmax (thin film cm−1): 926 (m), 1026 (s), 1099 (m), 1157 (m), 1182 (s), 1296 (m), 
1330 (m), 1445 (m), 1471 (s), 1518 (m), 1592 (s), 2137 (s), 2871 (m), 2977 (m). LRMS (ESI+): Found 
301.1 [M+Na]+. HRMS (ESI+): Found 301.0722 [M+Na]+, C12H14N4O2S + Na+ requires 301.0730. 
Aziridinopyrrolobenzothiadiazepine (17). The N-(2'-azidobenzenesulfonyl)-2-ethenylpyrrolidine (15) 
(125 mg, 0.449 mmol) was dissolved in toluene (10 mL) and heated to reflux for 18 h. The reaction was 
allowed to reach room temperature before the solvent was removed and the crude was purified by silica 
chromatography (25 g) (EtOAc/Hex;2:3) to yield the aziridine product 17 as a tan colored oil (50 mg, 
44%). NMR: δH (500 MHz, CDCl3): 1.81–2.07 (4H, m, 2 × CH2), 2.91–2.95 (1H, m, SO2NCHH), 3.32 
(1H, dd, J = 9.9, 11.7, ArNCHH), 3.50 (1H, m, SO2NCHH), 3.57 (1H, dd, J = 3.9, 11.7, ArNCHH), 3.89 
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(1H, ddd, J = 2.9, 2.9, 7.9, SO2NCH), 4.84–4.87 (1H, m, ArNCH), 6.70 (1H, d, J = 8.1, ArH), 6.84 (1H, 
dd, J = 7.8, 7.8, ArH), 7.20 (1H, ddd, J = 7.8, 7.8, 1.3, ArH), 7.70 (1H, dd, J = 8.1, 1.3, ArH); δC (125 
MHz, CDCl3): 24.5 (CH2), 25.8 (CH2), 43.4 (CH2), 49.2 (CH2), 59.3 (CH), 62.9 (CH), 118.6 (CH), 119.9 
(CH), 125.7 (q), 129.2 (CH), 132.7 (CH), 144.6 (q). IR: υmax (thin film cm−1): 759 (s), 1009 (m), 1037 
(m), 1081 (s), 1127 (s), 1274 (m), 1333 (s), 1482 (s), 1520 (m), 1591 (s), 2926 (m), 2970 (w), 3066 (m), 
3362 (w). LRMS (ESI+): Found 273.1 [M+Na]+, 523.1 [2M+Na]+, C12H14N2NaO2S requires 273.1. 
HRMS (ESI+): Found 251.0845 [M+H]+, C12H14N2O2S + H+ requires 251.0849. 
Synthesis of 1-[2'-Azido-4-(benzyloxy)-5-methoxybenzoyl]prolinal (37) 
Step 1: Synthesis of 1-[2'-Azido-4-(benzyloxy)-5-methoxybenzoyl]prolinol 
2'-Azido-4-(benzyloxy)-5-methoxybenzoic acid (236 mg, 0.789 mmol) was dissolved in dry toluene  
(5 mL) and SOCl2 (1.5 mL) was added. The solution was placed in a preheated oil bath at 85 °C for  
3 h. The reaction was cooled to ambient temperature, concentrated in vacuo, dissolved in fresh DCM  
(3 × 10 mL) and concentrated in vacuo, to remove the excess SOCl2. K2CO3 (218 mg, 1.58 mmol) in 
water (2 mL) was added in one portion to a stirring solution of S-prolinol (0.162 mL, 168 mg,  
1.66 mmol) in DCM (2 mL) and the whole was stirred for 10 min. The acid chloride in DCM (5 mL) 
was added drop-wise and the whole was stirred at ambient temperature overnight before the organic 
layer was separated. The aqueous phase was extracted with DCM (3 × 10 mL) and the combined organic 
layers were dried (MgSO4), filtered, concentrated and purified by silica chromatography (20 mg) 
(EtOAc/Hex; 3:1) to yield the product as an orange oil (262 mg, 87%). NMR: δH (400 MHz, CDCl3): 
1.56–1.84 (3H, m, CH2 + CHH), 2.06–2.13 (1H, m, CHH), 3.20–3.30 (2H, m, CH2), 3.62–3.67 (1H, m, 
CHHOH), 3.73–3.77 (1H, m, CHHOH), 3.80 (3H, s, OMe), 4.23–4.29 (1H, m, CHCH2OH), 4.69 (1H, 
bs, CH2OH), 5.10 (2H, s, OCH2), 6.59 (1H, s, ArH), 6.76 (1H, s, ArH), 7.24–7.38 (5H, m, ArH); δC  
(100 MHz, CDCl3): 24.5 (CH2), 28.5 (CH2), 49.6 (CH2), 56.3 (CH3), 61.2 (CH), 66.6 (CH2), 71.2 (CH2), 
104.2 (CH), 110.7 (CH), 121.4 (q), 127.3 (CH), 128.2 (CH), 128.7 (CH), 135.9 (q), 147.2 (q), 149.8 (q), 
168.8 (q). IR: υmax (thin film cm−1): 742 (s), 1004 (m), 1048 (m), 1077 (m), 1178 (s), 1214 (s), 1242 (s), 
1433 (s), 1511 (s), 1603 (s), 2109 (s), 2882 (w), 2937 (w), 3145–3593 (br). LRMS (ESI+): Found 383.2 
[M+H]+, 765.3 [2M+H]+, 787.3 [2M+Na]+. HRMS (ESI+): Found 383.1708 [M+H]+, C20H22N4O4 + H+ 
requires 383.1714. 
Step 2: Oxidation to 1-[2'-azido-4-(benzyloxy)-5-methoxybenzoyl]prolinal (37) 
DMSO (0.14 mL, 154 mg, 1.97 mmol) in DCM (1 mL) and the alcohol from the previous step  
(250 mg, 0.654 mmol) in DCM (2 mL) were added dropwise, respectively, over 15 min, to a solution of 
2 M oxalyl chloride (0.39 mL, 0.785 mmol) at −78 °C in DCM (1 mL). After 10 min, Et3N (0.24 mL,  
174 mg, 1.72 mmol) was added dropwise to the mixture at −78 °C. The whole was allowed to reach 
room temperature over two h before being quenched with a mixture of Et2O (10 mL) and H2O  
(10 mL). The organic layer was separated and the aqueous layer was extracted with DCM (3 × 10 mL). 
The combined organics were dried (MgSO4), filtered, concentrated and purified by silica 
chromatography (20 g) (EtOAc/Hex; 3:1) to give the product as a mixture of rotamers in the form of an 
orange oil (161 mg, 65%). NMR: δH (400 MHz, CDCl3): 1.79–1.89 (2H, m, CH2), 1.97–2.04 (1H, m, 
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CHH), 2.07–2.20 (1H, m, CHH), 3.28–3.34 & 3.35–3.41 (2H, m, NCH2), 3.76 & 3.81 (3H, 2 × s, OCH3), 
4.12–4.17 & 4.52–4.57 (1H, m, NCHCHO), 5.08 & 5.12 (2H, 2 × s, OCH2), 6.53 & 6.61 (1H, 2 × s, 
ArH), 6.72 & 6.80 (1H, 2 × s, ArH), 7.24–7.39 (5H, m, ArH), 9.22 & 9.62 (1H, 2 × d, J = 1.4 & 1.8, CHO); 
δC (100 MHz, CDCl3): 24.9/26.4 (CH2), 46.8/48.6 (CH2), 56.3/56.4 (CH3), 60.4 (CH2), 64.8/66.5 (CH), 
71.3/71.3 (CH2), 104.2/104.4 (CH), 111.2/111.5 (CH), 120.7/120.8 (q), 127.4 (CH), 128.3 (CH), 128.8 
(CH), 135.9/136.0 (q), 147.3/147.3 (q), 150.0/150.1 (q), 167.2/167.4 (q), 198.0/199.4 (CH). IR: υmax 
(thin film cm−1): 1245 (s), 1430 (s), 1454 (s), 1512 (s), 1604 (s), 1622 (s), 1731 (m), 2110 (s), 2942 (m). 
LRMS (ESI+): Found 381.2 [M+H]+, 403.1 [M+Na]+, 783.3 [2M+Na]+. HRMS (ESI+): Found 403.1375 
[M+Na]+, C20H20N4O4 + Na+ requires 403.1377.  
(1-(2'-Azidobenzenesulfonyl)pyrrolidin-2-yl)methanol (29). 2-Azidobenzenesulfonic acid (2.95 g,  
14.8 mmol) was heated at reflux in a 2M solution of (COCl)2 in dichloromethane (14.8 mL, 29.6 mmol) 
with a drop of DMF under an inert atmosphere of nitrogen for 5 h. The reaction was allowed to reach 
room temperature before the crude acid chloride was concentrated in vacuo and washed with 
dichloromethane (3 × 10 mL). K2CO3 (3.30 g, 23.7 mmol) in water (10 mL) was added in one portion 
to a stirring solution of L-prolinol (0.60 g, 5.9 mmol) in dichloromethane (15 mL). The crude sulfonyl 
chloride in dichloromethane (10 mL) was added slowly and the whole was stirred for 18 h at room 
temperature. The organic layer was separated and the aqueous layer was extracted with ethyl acetate  
(3 × 10 mL). The combined organic layers were dried (MgSO4), filtered, and concentrated to give the 
product as a pure orange oil (1.61 g, 96% from prolinol). NMR: δH (400 MHz, CDCl3): 1.67–1.78 (1H, 
m, CHH), 1.79–1.99 (3H, m, CHH + CH2), 2.79 (1H, bs, CH2OH), 3.38 (1H, dt, J = 6.3, 10.2, NCHH), 
3.49–3.56 (1H, m, NCHH), 3.62 (1H, dd, J = 5.6, 11.5, CHHOH), 3.70 (1H, dd, J = 4.2, 11.5, CHHOH), 
4.02–4.08 (1H, m, CHCH2OH), 7.27 (1H, ddd, J = 1.0, 7.8, 7.8, ArH), 7.32 (1H, dd, J = 1.0, 8.0, ArH), 
7.62 (1H, ddd, J = 1.5, 7.8, 7.8, ArH), 8.02 (1H, dd, J = 1.5, 8.0, ArH); δC (100 MHz, CDCl3): 24.7 
(CH2), 29.0 (CH2), 49.5 (CH2), 61.8 (CH), 65.5 (CH2), 119.9 (CH), 124.8 (CH), 129.0 (q), 132.6 (CH), 
134.2 (CH), 138.2 (q). IR: υmax (thin film cm−1): 819, 870, 900, 928, 992, 1043, 1069, 1122, 1146, 1155, 
1199, 1264, 1287, 1323, 1439, 1471, 1574, 1583, 1660, 2120, 2876, 2953, 3172–3693 (br). LRMS 
(ESI+): Found 305.1 [M+Na]+, 587.1 [2M+Na]+, C11H14N4O3S + Na+ requires 305.1. HRMS (ESI+): 
Found 305.0676 [M+Na]+, C11H14N4O3S + Na+ requires 305.0679. 
(1-(2′-Azidobenzenesulfonyl)pyrrolidin-2-yl)carbaldehyde (31). A 2M solution of oxalyl chloride in 
dichloromethane (1.88 mL, 3.75 mmol) was diluted with dichloromethane (10 mL) and cooled to −78 °C 
under nitrogen. DMSO (0.53 mL, 0.59 g, 7.5 mmol) in dichloromethane (10 mL) and the alcohol 29 
(0.80 g, 2.83 mmol) in dichloromethane (5 mL) were each added over 10 min. The whole was maintained 
at −78 °C for 30 min before dropwise addition of Et3N (2.18 mL, 1.58 g, 15.6 mmol) after which the 
whole was allowed to reach room temperature. The reaction was quenched with a mixture of Et2O  
(10 mL) and H2O (10 mL). The organic layer was separated and the aqueous phase was extracted with 
dichloromethane (3 × 10 mL). The combined organic layers were dried (MgSO4), filtered, concentrated 
and purified on silica (20 g) (EtOAc/Hex; 2:3) to yield the product as a white solid (0.57 g, 72%) which 
rapidly decomposed to an orange oil and was used immediately in subsequent reactions. NMR: δH  
(400 MHz, CDCl3): 1.83–1.95 (2H, m, CH2), 1.98–2.09 (1H, m, CHH), 2.15–2.23 (1H, m, CHH), 3.40 
(1H, dt, J = 9.7, 7.2, NCHH), 3.57 (1H, ddd, J = 5.5, 6.8, 9.7, CHH), 4.47 (1H, ddd, J = 1.9, 4.5, 8.5, 
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CHCHO), 7.28 (1H, ddd, J = 7.8, 7.8, 1.0, ArH), 7.34 (1H, dd, J = 8.0, 1.0, ArH), 7.64 (1H, ddd, J = 7.8, 
7.8, 1.6, ArH), 8.03 (1H, dd, J = 8.0, 1.6, ArH), 9.72 (1H, d, J = 1.6, CHO); δC (100 MHz, CDCl3): 25.0 
(CH2), 27.7 (CH2), 48.8 (CH2), 67.1 (CH), 119.9 (CH), 124.9 (CH), 128.9 (q), 132.5 (CH), 134.4 (CH), 
138.2 (q), 200.5 (CH). IR: υmax (thin film cm−1): 820, 865, 999, 1080, 1122, 1156, 1199, 1265, 1287, 
1332, 1439, 1471, 1574, 1583, 1603, 1730, 2122, 2953. HRMS (ESI+): compound degraded. 
N-(2'-Azidobenzoyl)-2-(carbethoxy-1''-ethenyl)-pyrrolidine (32). The aldehyde 30 [33,34] (273 mg,  
1.12 mmol) was dissolved in toluene (10 mL). (Carbethoxymethylene) triphenylphosphorane (390 mg, 
1.12 mmol) was added in one portion and the whole was stirred at room temperature under an inert 
atmosphere of nitrogen for 12 h before being concentrated in vacuo and purified by silica chromatography 
(40 g) (EtOAc/Hex; 3:2) to yield the product 32 in the form of a yellow oil as a mixture of rotamers  
(178 mg, 51%). NMR: δH (400 MHz, CDCl3): 1.29 & 1.31 (3H, t, J = 7.1, 2 × COCH2CH3), 1.80–1.99 & 
2.01–2.43 (4H, m, CH2), 3.21–3.28 & 3.78–3.86 (1H, m, CHH), 3.34–3.40 & 3.69–3.75 (1H, m, CHH), 
4.13 & 4.21 (2H, q, J = 7.1 & 7.1, COCH2CH3), 4.24–4.30 & 4.96–5.00 (1H, m, NCHCH2), 5.46 & 6.15 
(1H, dd & d, J = 15.6, 1.1 & 15.6, CHCHCO2Et), 6.59 & 6.94 (1H, dd & dd, J = 15.6, 6.4 & 15.6, 4.9, 
CHCHCO2Et), 7.12 (1H, dd, J = 7.5, 7.5, ArH), 7.14 (1H, d, J = 7.3, ArH), 7.19–7.25 (1H, m, ArH), 
7.40 & 7.45 (2H, 2 × m, ArH); δC (100 MHz, CDCl3): 14.2/14.3 (CH3), 22.3/23.8 (CH2), 30.5/32.1 (CH2), 
46.1/48.2 (CH2), 57.2 (CH), 60.4/60.6 (CH2), 118.5 (CH), 121.2/121.3 (CH), 124.9/125.2 (CH), 127.9 
(CH), 129.1/129.5 (q), 130.6 (CH), 133.7/136.2 (q), 146.5 (CH), 165.8/166.5 (q), 167.1/167.4 (q). IR: υmax 
(thin film cm−1): 753 (s), 1043 (m), 1093 (m), 1180 (s), 1301 (s), 1369 (m), 1414 (s), 1451 (s), 1475 (m), 
1633 (s), 1716 (s), 2130 (s), 2238 (w), 2880 (m), 2979 (m). LRMS (ESI+): Found 315.1 [M+H]+, 337.1 
[M+Na]+, 651.3 [2M+Na]+. HRMS (ESI+): Found 315.1451 [M+H]+, C16H18N4O3 + H+ requires 315.1452. 
Aziridinopyrrolobenzodiazepine (33). The carbethoxy alkene 32 (178 mg, 0.567 mmol) was heated at 
reflux under nitrogen in CHCl3 (10 mL) for 48 h before being concentrated and purified by silica 
chromatography (20 g) (EtOAc/Hex; 3:2) to yield the product 33 as a ~1:1 mixture of two 
diastereoisomers in the form of a yellow oil (47 mg, 30%). NMR: δH (400 MHz, CDCl3) [mixture of 
isomers]: 1.23 (3H, t, J = 7.1, COCH2CH3, isomer “a”), 1.29 (3H, t, J = 7.1, COCH2CH3, isomer “b”), 
1.74–1.80 (2H, m, CH2),1.81–2.27 (4H, m, 2 × CH2), 2.77 (1H, d, J = 2.6, CHCO2Et, isomer “a”), 2.87 
(1H, d, J = 2.7, CHCO2Et, isomer “b”), 3.08 (1H, dd, J = 9.6, 2.6, ArNCH, isomer “a”), 3.37 (1H, dd,  
J = 8.7, 2.7, ArNCH, isomer “b”), 3.57 (1H, ddd, J = 7.3, 7.3, 12.0, CHH), 3.66–3.73 (4H, m, 2 × CH2), 
3.74–3.79 (1H, m, CONCH), 3.78–3.87 (1H, m, CHH), 4.20 (2H, quartet, J = 7.1, COCH2CH3, isomer 
“a”), 4.23 (2H, quartet, J = 7.1, COCH2CH3, isomer “b”), 4.38 (1H, bd, J = 9.6, CONCH), 6.69 (1H, d, 
J = 7.4, ArH), 6.94 (1H, ddd, J = 7.5, 7.5, 0.9, ArH), 7.01 (1H, ddd, J = 7.5, 7.5, 1.0, ArH), 7.07 (1H, 
d, J = 8.0, ArH), 7.19 (1H, ddd, J = 7.6, 7.6, 1.6, ArH), 7.28 (1H, ddd, J = 7.7, 7.8, 1.6, ArH), 7.70 (2H, 
dd, J = 7.8, 1.8, ArH); δC (100 MHz, CDCl3): 14.2 (CH3), 14.5 (CH3), 23.1 (CH2), 25.6 (CH2), 29.5  
(2 × CH2), 42.6 (CH), 46.4 (CH2), 47.0 (CH), 50.4 (CH), 56.6 (CH), 57.2 (CH), 60.1 (CH), 61.4 (CH2), 
62.0 (CH2), 68.0 (CH2), 121.3 (CH), 122.0 (CH), 123.1 (CH), 123.3 (CH), 125.3 (q), 126.6 (q), 130.7 
(CH), 131.0 (CH), 132.0 (CH), 132.2 (CH), 142.9 (q), 148.1 (q), 166.0 (q), 166.3 (q), 167.9 (q), 168.8 
(q). IR: υmax (thin film cm−1): 752 (m), 1024 (s), 1178 (s), 1217 (s), 1260 (s), 1372 (m), 1454 (m), 1503 
(m), 1602 (s), 1622 (s), 1725 (s), 2871 (m), 2926 (m), 2977 (m). LRMS (ESI+): Found. 309.1 [M+Na]+. 
HRMS (ESI+): Found 309.1206 [M+Na]+, C16H18N2O3 + Na+ requires 309.1210. 
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Aziridinopyrrolobenzothiadiazepine (35). The aldehyde 31 (286 mg, 1.13 mmol) was dissolved in 
toluene (10 mL) and (carbethoxymethylene) triphenylphosphorane (500 mg, 1.43 mmol) was added in 
one portion and the whole was stirred at room temperature for 18 h. The reaction mixture was concentrated 
and purified by silica chromatography (40 g) (EtOAc/Hex; 3:2) to yield, as a single isomer, the aziridine 
35 as a yellow oil (123 mg, 34%). NMR: δH (500 MHz, CDCl3): 1.41 (3H, t, J = 7.1, COCH2CH3),  
1.75–1.80 (1H, m, CHH), 1.87–2.01 (1H, m, CHH), 2.09–2.16 (1H, m, CHH), 2.27–2.35 (1H, m, CHH), 
3.19 (1H, ddd, J = 5.0, 9.6, 9.6, SO2NCHH), 3.67–3.73 (2H, m, SO2NCHH + CHCHCH), 4.08 (1H, ddd, 
J = 2.1, 7.4, 9.8, SO2NCH), 4.33–4.40 (2H, m, COCH2CH3), 4.94 (1H, d, J = 9.8, ArNCH), 7.43 (1H, ddd, 
J = 7.7, 7.7, 1.1, ArH), 7.55 (1H, dd, J = 8.0, 1.1, ArH), 7.60 (1H, ddd, J = 7.7, 7.7, 1.5, ArH), 8.04 (1H, dd, 
J = 8.0, 1.5, ArH); δC (125MHz, CDCl3): 14.1 (CH3), 22.7 (CH2), 28.9 (CH2), 46.4 (CH2), 60.7 (CH), 61.8 
(CH), 63.0 (CH2), 85.4 (CH), 123.8 (CH), 126.6 (CH), 128.5 (CH), 131.6 (q), 133.6 (CH), 138.4 (q), 
167.3 (q). IR: υmax (thin film cm−1): 1035 (m), 1066 (m), 1092 (s), 1135 (m), 1167 (s), 1205 (m), 1247 (m), 
1271 (m), 1344 (s), 1469 (s), 1503 (m), 1589 (m), 1738 (s), 2981 (m). LRMS (ESI+): Found 345.1 [M+Na]+, 
723.2 [2M+Na]+. HRMS (ESI+): Found 345.0875 [M+Na]+, C15H18N2O4S + Na+ requires 345.0879. 
3-Benzyloxy-4-methoxy-11-ethyl-ethanoyl-[1,4]-pyrrolo[2,1-c] benzodiazepin-5-one (40). The aldehyde 
37 (198 mg, 0.58 mmol) was dissolved in toluene (10 mL) and (carbethoxy-methylene)triphenylphosphorane 
(200 mg, 0.58 mmol) was added in one portion and the whole was stirred at room temperature for 18 h. 
The reaction was concentrated in vacuo and purified by silica chromatography (30 g) (EtOAc/Hex; 4:1) 
to yield the product 40 as a yellow oil (52 mg, 21%). NMR: δH (500 MHz, CDCl3): 1.32 (3H, t, J = 7.2, 
CO2CH2CH3), 1.74–1.80 (1H, m, CHH), 1.93–2.19 (3H, m, CHH + CH2), 2.31–2.24 (2H, m, 
CH2CO2Et), 3.43–3.47 (1H, m, NHCH), 3.62–3.66 (1H, m, NHCHCH), 3.68–3.73 (1H, m, NCHH), 
3.76–3.80 (1H, m, NCHH), 3.89 (3H, s, OMe), 4.22 (2H, q, J = 7.2, CO2CH2CH3), 5.13 (1H, d, J = 12.3, 
PhCHHO), 5.18 (1H, d, J = 12.3, PhCHHO), 6.34 (1H, s, ArH), 7.31–7.50 (7H, m, 6 × ArH + NH); δC 
(125 MHz, CDCl3): 14.2 (CH3), 23.2 (CH2), 29.9 (CH2), 37.3 (CH2), 46.9 (CH2), 56.3 (CH3), 60.1 (CH), 
61.0 (CH2), 62.7 (CH), 70.9 (CH2), 108.1 (CH), 113.1 (CH), 120.0 (q), 127.4 (CH), 128.0 (CH), 128.4 
(CH), 136.5 (q), 137.8 (q), 145.0 (q), 150.9 (q), 168.3 (q), 171.9 (q). IR: υmax (thin film cm−1): 723 (m), 
1025 (s), 1119 (s), 1178 (s), 1218 (s), 1260 (s), 1373 (m), 1432 (s), 1453 (m), 1503 (m), 1602 (s), 1623 
(m), 1726 (m), 2860 (m), 2924 (s), 2953 (m). LRMS (ESI+): Found 447.2 [M+Na]+. HRMS (ESI+): 
Found 447.1895 [M+Na]+ requires C24H28N2O5 + Na+ requires 447.1890. 
3.3. Synthesis and Reactivity of the Azetidino-Based Systems 
4-Methyl-4-ethenyl-1-azetidin-2-one (41a). To a stirred solution of isoprene (2.33 g, 3.43 mL, 34.41 mmol) 
in dry diethyl ether (15 mL) at –78 °C was added a solution of chlorosulfonyl isocyanate (4.88 g,  
3.01 mL, 34.01 mmol) in dry ether (10 mL) dropwise over one hour. The reaction mixture was allowed 
to warm to −10) dropwise over one hour. The reaction mixture was allowed to warm to −10 °C and then 
the reaction flask was transferred to an ice-salt bath and stirred for 30 min. The cooled solution was 
added dropwise to a vigorously stirred solution of water (50 mL), sodium carbonate (9.00 g), sodium 
sulfite (6.01 g) and ice (30 g) over 10 min. The mixture was stirred at −10 °C for 1 h and then allowed to 
warm to room temperature and extracted with diethyl ether (6 × 20 mL). The combined organic extracts 
were dried (MgSO4) and the solvent removed under reduced pressure to give the product as a pale yellow 
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oil (2.20 g, 58%). NMR: δH (400 MHz, CDCl3): 1.50 (3H, s, Me), 2.79 (2H, s, CH2), 5.10 (1H, dd, J = 10.6, 
0.7, CH=CHH), 5.22 (1H, dd, J = 17.2, 0.7, CH=CHH), 6.02 (1H, dd, J = 10.6, 17.2, CH=CH2), 6.83 
(1H, br, NH); δC (100 MHz, CDCl3): 24.8 (CH2), 50.7 (CH3), 54.5 (q), 113.8 (CH), 141.1 (CH2), 167.6 
(q). IR: υmax (thin film cm−1): 923 (m), 1153 (m), 1186 (m), 1226 (m), 1274 (w), 1304 (m), 1372 (m), 
1412 (m), 1643 (m), 1720 (s), 2970 (w), 3235 (m). LRMS (ESI+): Found 134.1 [M+Na]+, 291.2 [2M+3Na]+. 
4-Methyl-4-ethenyl-1-azetidin-2-thione (43a). To the azetidin-2-one (0.55 g, 4.97 mmol) in dry THF (15 mL) 
was added Lawesson’s reagent (1.00 g, 2.48 mmol) and the whole was stirred at room temperature for 
an hour before being heated to reflux for two h. The reaction was cooled to ambient temperature before 
being concentrated under reduced pressure and purified by silica chromatography (75 g) (EtOAc/petroleum 
ether; 1:3) to give the product as a yellow oil (0.35 g, 56%). The reaction was higher yielding (up to 
70%) on a larger scale (2 g of lactam), but less convenient to purify (stench). NMR: δH (400 MHz, 
CDCl3): 1.60 (3H, s, Me), 2.98 (2H, s, CSCH2), 5.21 (1H, d, J = 10.6, CH=CHH), 5.28 (1H, d, J = 17.2, 
CH=CHH), 6.05 (1H, dd, J = 10.6, 17.2 CH=CH2), 8.78 (1H, bs, NH); δC (100 MHz, CDCl3): 23.8 
(CH3), 54.6 (CH2), 63.7 (q), 115.1 (CH2), 139.0 (CH), 202.2 (q). IR: υmax (thin film cm−1): 924 (s), 989 
(m), 1016 (m), 1081 (s), 1217 (m), 1288 (m), 1374 (m), 1404 (s), 1466 (s), 2971 (w), 3147 (m). 
4-Ethenyl-2-azetidinone (41b). To 1,3-butadiene (10 mL) condensed into anhydrous ether (40 mL) at 
−10 °C, was added a solution of chlorosulfonyl isocyanate (3.0 mL, 34.5 mmol) in anhydrous ether  
(10 mL) over one hour, under an atmosphere of nitrogen. The temperature was maintained at −10 °C for 
a further period of 3 h and warmed slowly to room temperature overnight, to produce a clear, yellow 
solution. The solution was added to an ice cold mixture of water (70 mL), ice (30 g), NaHCO3 (9.0 g) 
and Na2SO3 (6.0 g) and stirred for one hour at −10 °C. The reaction was allowed to warm to room 
temperature before being extracted with ether (6 × 20 mL). The combined organic layers were dried  
over anhydrous sodium sulfate, filtered and evaporated to dryness under reduced pressure to yield  
4-ethenyl-2-azetidinone (2.01 g, 60% yield) as a clear yellow oil. NMR: δH (400 MHz, CDCl3): 6.49 
(1H, s, N−H), 5.92 (1H, ddd, J = 17.2, 10.2, 3.2, =CH), 5.32 (1H, d, J = 17.2, =CH2), 5.20 (1H, d,  
J = 10.2, =CH2), 4.13 (1H, m, NCH), 3.25 (1H, m, ring-CH2), 2.70 (1H, d, J = 17.2 ring-CH2); δC  
(100 MHz, CDCl3): 167.82 (C=O), 137.43 (CH), 116.93 (CH2), 49.40 (CH2), 48.93 (CH). IR: υmax  
(thin film cm−1): 3274.6 (m, broad), 1755.4 (s), 1448.2 (m), 1413.8 (m), 1380.1 (m), 1254.7 (w). 
4-Ethenylazetidin-2-thione (43b). To the lactam (1.00 g, 10.3 mmol) dissolved in anhydrous THF  
(15 mL), was added Lawesson’s reagent (2.08 g, 5.15 mmol) in one portion, with stirring. The reaction 
was stirred at ambient temperature, under an inert atmosphere of dry nitrogen for one hour, before being 
heated at reflux for an additional hour. The reaction was monitored for completion by tlc and was 
subsequently cooled to room temperature, to give a crude product as a clear orange liquid. The sample 
was concentrated by rotary evaporation and purified using silica column chromatography (eluent: 
petroleum ether-ethyl acetate 4:1), to yield 4-ethenyl-azetidin-2-thione (0.67 g, 58%) as a clear, yellow 
oil. NMR: δH (400 MHz, CDCl3): 8.68 (1H, s, N−H), 5.96 (1H, ddd, J = 17.1, 10.3, 3.0, =CH), 5.35 (1H, 
d, J = 17.1, =CH2), 5.26 (1H, d, J = 10.3, =CH2), 4.62 (1H, m, NCH), 3.30 (1H, m, ring-CH2), 2.84 (1H, 
m, ring-CH2); δC (100 MHz, CDCl3): 203.65 (C=S), 135.14 (CH), 118.34 (CH2), 58.01 (CH), 48.34 
(CH2). IR: υmax (thin film cm−1): 3174.1 (m, broad), 1482.6 (s), 1426.0 (m), 1407.2 (w), 1237.1 (m).  
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1-(2′-Azidobenzoyl)-4-methyl-4-vinylazetidin-2-one (42a). 2-Azidobenzoic acid (508 mg, 3.02 mmol) 
was heated to reflux in SOCl2 (4 mL) for 3 h under nitrogen. The excess SOCl2 was removed in vacuo 
and the crude acid chloride was dissolved in DCM (3 × 5 mL) which was removed in vacuo to yield the 
crude 2-azidobenzoylchloride. The β-lactam 41 (457 mg, 4.12 mmol) in DCM (25 mL) and DMAP  
(100 mg) were chilled to −10 °C. The crude acid chloride in DCM (5 mL) was added dropwise to the 
solution over 10 min. The whole was maintained at −10 °C for 30 min before the addition of Et3N  
(0.89 mL, 646 mg, 6.40 mmol) and the whole was allowed to reach room temperature overnight.  
The reaction was concentrated under reduced pressure and purified by silica chromatography (70 g) 
(EtOAc/Hex; 1:4) to give the product 42a as a mixture of rotamers in the form of a dark yellow oil  
(498 mg, 65%). NMR: δH (400 MHz, CDCl3) rotamer 1: 1.87 (3H, s, Me), 2.98 (1H, d, J = 16.2, 
COCHH), 3.08 (1H, d, J = 16.2, COCHH), 5.35 (1H, d, J = 10.7, CHH=CH), 5.45 (1H, d, J = 17.3, 
CHH=CH), 6.24 (1H, dd, J = 10.7, 17.3, CH=CH2), 7.22 (1H, dd, J = 7.6, 7.6, ArH), 7.23 (1H, d, J = 8.3, 
ArH), 7.42 (1H, dd, J = 7.6, 1.4, ArH), 7.52 (1H, ddd, J = 8.3, 8.3, 1.4, ArH). δH (400 MHz, CDCl3) 
rotamer 2: 1.51 (3H, s, Me), 2.68 (1H, d, J = 15.8, COCHH), 2.82 (1H, d, J = 15.8, COCHH), 5.20 (1H, 
d, J = 10.6, CHHCH), 5.32 (1H, d, J = 17.2, CHHCH), 5.91 (1H, dd, J = 10.6, 17.2, CHCH2), 7.21 (1H, 
ddd, J = 7.6, 7.6, 0.9, ArH), 7.24 (1H, d, J = 7.6, ArH), 7.51 (1H, ddd, J = 7.8, 7.8, 1.5, ArH), 7.67 (1H, 
dd, J = 7.8, 1.5, ArH); δC (100 MHz, CDCl3) rotamer 1: 21.7 (CH3), 49.2 (CH2), 58.9 (q), 114.9 (CH2), 
117.5 (CH), 123.7 (CH), 125.8 (q), 128.1 (CH), 131.2 (CH), 137.1 (q), 137.2 (CH), 162.4 (q), 162.5 (q); 
δC (100 MHz, CDCl3) rotamer 2: 27.6 (CH3), 39.5 (CH2), 58.6 (q), 114.3 (CH2), 119.9 (CH), 123.5 (q), 
124.7 (CH), 130.8 (CH), 132.1 (CH), 138.9 (q), 139.9 (CH), 151.5 (q), 165.3 (q). IR: υmax (thin film 
cm−1): 1084 (m), 1216 (s), 1329 (s), 1391 (s), 1451 (m), 1478 (m), 1519 (s), 1604 (m), 1656 (m), 1682 
(m), 1801 (s), 2131 (s), 2853 (m), 2925 (m). LRMS (ESI+): 279.1 [M+Na]+, 535.2 [2M+Na]+. 
C13H12N4NaO2 requires 279.1. HRMS (ESI+): 279.0862 [M+Na]+, C13H12N4NaO2 requires 279.0852.  
8,9-Dimethylazetidino[2,1-a][1,4]benzodiazepin-2,11-dione (45). The azetidinone 42a (250 mg,  
0.97 mmol) was heated to reflux in CHCl3 (10 mL) under an atmosphere of dry nitrogen and monitored 
by NMR every 24 h. After 72 h, the reaction mixture was concentrated under reduced pressure and 
purified by silica chromatography (22 g) using graduated elution (EtOAc/Hex; 1:4–3:1) to give the imine 
45 as a yellow oil (84 mg, 38%). NMR: δH (500 MHz, CDCl3): 2.00 (3H, s, Me), 2.49 (1H, s, Me), 3.42 
(1H, d, J = 16.0, COCHH), 3.77 (1H, d, J = 16.0, COCHH), 7.52 (1H, ddd, J = 7.7, 7.7, 1.0, ArH), 7.70 
(1H, dd, J = 8.0, 1.0, ArH), 7.78 (1H, ddd, J = 7.7, 7.7, 1.6, ArH), 8.32 (1H, dd, J = 8.0, 1.6, ArH); δC 
(125MHz, CDCl3): 20.1 (CH3), 26.2 (CH3), 43.6 (CH2), 73.3 (q), 123.7 (q), 126.5 (CH), 126.7 (CH), 
127.4 (CH), 134.3 (CH), 149.7 (q), 155.2 (q), 158.1(q), 204.2 (q). IR: υmax (thin film cm−1): 702 (s), 730 
(s), 1264 (s), 1421 (m), 1463 (m), 1609 (m), 1657 (m), 1686 (m), 1721 (s), 1799 (m), 2928 (w). LRMS 
(ESI+): Found 229.1 [M+H]+, 251.1 [M+Na]+, 479.2 [2M+Na]+. HRMS (ESI+): Found 229.0978 
[M+H]+, 479.1703 [2M+Na], C13H13N2O2 requires 229.0972 and C26H24N4NaO4 requires 479.1690. 
1-(2′-Azidobenzoyl)-4-methyl-4-vinyl-1-azetidin-2-thione (44a). 2-Azidobenzoic acid (214 mg, 1.3 mmol) 
was heated to reflux under nitrogen in SOCl2 (4 mL) for 4 h. The excess thionyl chloride was removed 
in vacuo and the product was dissolved in DCM (3 × 5 mL) and concentrated in vacuo to give the crude 
acid chloride. The thiolactam (250 mg, 1.97 mmol) in DCM (25 mL) and DMAP (100 mg) was chilled 
to −10 °C. The crude acid chloride in DCM (5 mL) was added dropwise over 10 min and the whole was 
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maintained at −10 °C for 30 min before dropwise addition of Et3N (0.41 mL, 299 mg, 2.95 mmol).  
The whole was allowed to reach room temperature overnight and the reaction was concentrated and 
purified by silica chromatography (22 g) (EtOAc/Hex; 1:4) to give the product 44a as an orange oil  
(296 mg, 84%). NMR: δH (400 MHz, CDCl3): 1.92 (3H, s, Me), 2.93 (1H, d, J = 16.9, CSCHH), 3.04 
(1H, d, J = 16.9, CSCHH), 5.38 (1H, d, J = 10.8, CHH=CH), 5.45 (1H, d, J = 17.3, CHH=CH), 6.31 
(1H, dd, J = 17.3, 10.8 CHH=CH), 7.20 (1H, dd, J = 8.2, 0.8, ArH), 7.24 (1H, ddd, J = 7.6, 7.6, 0.8, 
ArH), 7.36 (1H, dd, J = 7.6, 1.5, ArH), 7.54 (1H, ddd, J = 8.2, 8.2, 1.5, ArH); δC (100 MHz, CDCl3): 
22.3 (CH3), 54.5 (CH2), 67.5 (q), 116.4 (CH2), 118.5 (CH), 125.1 (CH), 126.6 (q), 128.9 (CH), 132.1 
(CH), 137.7 (CH), 138.3 (q), 164.2 (q), 201.7 (q). IR: υmax (thin film cm−1): 909 (s), 931 (m), 1215 (s), 
1322 (s), 1358 (m), 1448 (w), 1478 (m), 1674 (s), 2131 (s). LRMS (ESI+): Found 295.1 [M+Na]+, 567.1 
[2M+Na]+. HRMS (ESI+): Found 295.0623 [M+Na]+, C13H12N4NaOS requires 295.0624.  
12-Methyl-1,2,3-triazolino[1,5-a]azetidino[1,4-c][1,4]benzodiazepin-2-on-14-thione (46). The 1-(2'-
azidobenzoyl)-azetidin-2-thione 44a (295 mg, 1.08 mmol) was heated at reflux in CHCl3 (10 mL) under 
nitrogen for 36 h before being concentrated under reduced pressure and purified by silica chromatography 
(22 g) (EtOAc/Hex; 1:1) to give the triazolino product 46 as a yellow oil (180 mg, 61%). NMR: δH  
(500 MHz, CDCl3): 1.22 (3H, s, Me), 2.89 (1H, d, J = 16.8, SCCHH), 2.94 (1H, d, J = 16.8, SCCHH), 
4.27 (1H, dd, J = 6.1, 12.2, CH3CHN), 4.37 (1H, dd, J = 6.1, 17.7, N3CHH), 4.71 (1H, dd, J = 12.2, 17.7, 
N3CHH), 7.14 (1H, ddd, J = 7.1, 7.1, 1.0, ArH), 7.52 (1H, ddd, J = 7.2, 7.2, 1.6, ArH), 8.04 (1H, dd,  
J = 8.4, 1.0, ArH), 8.2 (1H, dd, J = 8.4, 1.6, ArH); δC (125 MHz, CDCl3): 16.8 (CH3), 50.5 (CH2), 59.6 
(CH), 65.0 (q), 70.4 (CH2), 115.9 (q), 118.6 (CH), 123.4 (CH), 134.2 (CH), 134.5 (CH), 138.3 (q), 161.8 
(q), 198.1 (q). IR: υmax (thin film cm−1): 745 (s), 1103 (m), 1162 (m), 1211 (m), 1251 (m), 1322 (s), 1461 
(s), 1483 (s), 1607 (s), 1651 (s), 1678 (s), 1720 (m), 2921 (w), 3000 (w). LRMS (ESI+): Found 295.1 
[M+Na]+, 567.1 [2M+Na]+. HRMS (ESI+): Found 295.0622 [M+Na]+, C13H12N4NaOS requires 295.0624.  
11-Thioxo-8,9-dimethyl-azetidino[2,1-c][1,4]benzodiazepin-2-one (47). A sample of the triazolo 
compound 46 from above (87 mg, 0.32 mmol) was heated at reflux in CHCl3 (10 mL) under nitrogen 
for a week before being concentrated under reduced pressure and purified by silica chromatography (15 g) 
(EtOAc/Hex; 3:2) to give the methyl imine product as a yellow oil (25 mg, 32%). NMR: δH (400 MHz, 
CDCl3): 1.98 (3H, s, Me), 2.47 (3H, s, Me), 3.40 (1H, d, J = 16.0, CSCHH), 3.77 (1H, d, J = 16.0, 
CSCHH), 7.50 (1H ddd, J = 7.7, 7.7, 1.0, ArH), 7.68 (1H, d, J = 8.1, ArH), 7.77 (1H, ddd, J = 7.7, 7.7, 
1.4, ArH), 8.30 (1H, dd, J = 8.1, 1.4, ArH); δC (100 MHz, CDCl3): 20.1 (CH3), 26.3 (CH3), 43.6 (CH2), 
73.3 (q), 123.6 (q), 126.6 (CH), 126.7 (CH), 127.3 (CH), 134.3 (CH), 149.6 (q), 155.2 (q), 158.0 (q), 
204.4 (q). IR: υmax (thin film cm−1): 647 (s), 770 (s), 1103 (m), 1115 (m), 1132 (m), 1300 (m), 1323 (s), 
1346 (s), 1460 (s), 1606 (s), 1651 (s), 1676 (s), 2928 (w), 2975 (w). LRMS (ESI+): Found 267.1 
[M+Na]+. HRMS (ESI+): Found 267.0551 [M+Na]+, C13H12N2NaOS requires 267.0563. 
1-(2′-Azidobenzoyl)-4-ethenyl-1-azetidin-2-thione (44b). To a solution of 4-ethenyl-1-azetidin-2-thione 
(43b, 0.16 g, 1.42 mmol) and dimethylaminopyridine (0.1 g, 0.82 mmol) in anhydrous dichloromethane 
(20 mL), was added, with stirring and under an atmosphere of dry nitrogen, 2-azidobenzoylchloride 
(0.28 g, 1.56 mmol) in anhydrous dichloromethane (10 mL) [prepared as described previously], dropwise 
over 20 min at −10 °C. The reaction was stirred for 30 min before triethylamine (0.29 mL, 2.83 mmol) 
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was added dropwise over 10 min at −10 °C. The reaction mixture was warmed to room temperature and 
left to stir at ambient temperature for 24 h, before being concentrated by rotary evaporation under 
reduced pressure and purified by flash silica column chromatography (eluent: petroleum ether-ethyl 
acetate, 4:1) to yield 1-(o-azidobenzoyl)-4-ethenyl-1-azetidin-2-thione (0.26 g, 71%) as a yellow solid, 
melting point: 79–82 °C. NMR: δH (500 MHz, CDCl3): 2.84 (1H, dd, J = 17.1, 3.1, CHH). 3.24 (1H, dd, 
J = 17.1, 5.9, CHH), 5.15 (1H, m, CH), 5.38 (1H, d, J = 10.4, CHH=CH), 5.49 (1H, d, J = 17.2, 
CHH=CH), 6.09 (1H, ddd, J = 17.2, 10.4, 7.0, =CH), 7.21 (2H, m, 2 × ArH), 7.39 (1H, dd, J = 7.6, 1.2, 
ArH), 7.53 (1H, ddd, J = 7.8, 7.8, 1.5, ArH); δC (125 MHz, CDCl3): 47.10 (CH2), 59.42 (CH), 118.52 
(CH), 119.46 (CH2), 124.97 (CH), 126.06 (q), 129.32 (CH), 132.40 (CH), 133.59 (CH), 163.97 (C=O), 
201.89 (C=S). IR: υmax (thin film cm−1): 2927.9 (s), 2853.4 (s), 2128.3 (s), 1687.0 (s), 1462.9 (m), 1375.5 
(m), 1303.6 (m). HRMS (ESI+): calc. for C12H10N4OS + H+ = 259.0648, measured = 259.0648.  
(Aziridino[1,2-a]azetidino[2,1-c])[1,4]benzodiazepine-7-one-9-thione (48). A solution of 1-(2'-
azidobenzoyl)-4-ethenyl-1-azetidin-2-thione (44b, 0.074 g, 2.87 mmol) dissolved in anhydrous toluene 
(6 mL) was heated at reflux under an atmosphere of dry nitrogen for 24 h at which point TLC confirmed 
that the reaction had gone to completion. The sample was cooled to room temperature, concentrated 
under reduced pressure, and purified by silica column chromatography (eluent: petroleum ether:ethyl 
acetate, 1:2) to yield the title compound 48 (0.032 g, 48% yield) as a yellow oil. NMR: δH (500 MHz, CDCl3): 
2.26 (1H, d, J = 3.5, NCHH), 2.81 (1H, d, J = 4.4, NCHH), 3.10 (1H, dd, J = 16.8, 2.8, CSCHH), 3.17 
(1H, ddd, J = 8.9, 4.4, 3.5, ArNCH), 3.31 (1H, dd, J = 16.8, 5.7, CSCHH), 4.20 (1H, ddd, J = 8.9, 5.7, 
2.8, CONCH), 7.10 (1H, ddd, J = 7.6, 7.6, 0.8, ArH), 7.17 (1H, d, J = 8.1, ArH), 7.45 (1H, ddd, J = 7.7, 
7.7, 1.6, ArH), 7.80 (1H, dd, J = 8.1, 1.6, ArH); δC (125 MHz, CDCl3): 35.13 (CH2), 42.00 (CH), 45.14 
(CH2), 58.86 (CH), 122.90 (CH), 123.47 (CH), 132.20 (CH), 133.76 (CH), 150.04 (q), 163.89 (C=O), 
199.55 (C=S). IR: υmax (thin film cm−1): 2873.3 (w), 1698.2 (s), 1653.5 (s), 1601.9 (m), 1483.4 (m), 1355.8 
(m), 1345.6 (s), 1195.4 (m). HRMS (ESI+): calc. for C12H10N2OS + H+ = 231.0587, measured = 231.0588. 
4. Conclusions 
Intramolecular 1,3-dipolar cycloadditions between an azide and an alkene in 1-(2'-azidoaroyl)-2-alkenyl-
proline based systems led to aziridino-fused pyrrolobenzodiazepines and pyrrolobenzothiadiazepines  
(4 examples), or to pyrrolobenzodiazepines with a methyl substituted imine (1 example) or a 
pyrrolobenzodiazepine with a carbethoxymethylene substituted amine (1 example). 1-(2'-Azidoaroyl)-
4-alkenyl-azetidin-2-ones reacted to give the corresponding aziridino-fused azetidinobenzodiazepine  
(1 example), triazolino-fused azetidinobenzodiazepine (1 example) or azetidinobenzodiazepine with a 
methyl substituted imine (2 examples). These reactivity patterns are unpredictable but can all be 
rationalized by the formation of a common triazoline intermediate. We are currently further exploring 
the chemistry of the 4-ethenyl-1-azetidin-2-one derivatives 41–44 and are also investigating the antitumour 
and antibiotic potential of the PBD, PBTD and azetidinobenzodiazepines reported in this paper. 
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